U.S. FDA Approves Labeling Update of REXULTI (brexpiprazole) For Maintenance Treatment of Schizophrenia

Pharmacy Choice
September 23, 2016
Dr. Christoph U. Correll, Professor, Psychiatry, Hofstra Northwell School of Medicine, Medical Director, Recognition & Prevention Program (RAP), Zucker Hillside Hospital

 

Topics: News

Focus onHealth TV

Watch Focus onHealth, Northwell Health's TV show. It's the healthy way to stay informed!